메뉴 건너뛰기




Volumn 136, Issue 3, 2015, Pages 693-696

Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study

Author keywords

Abbreviations HTI Hemoclot Thombin Inhibitors ; CV Coefficient of variation expressed in percentage; ECA Ecarin chromogenic assay; LOD Limit of detection; LOQ Limit of quantification; NIH ml National Institutes of Health (NIH) units per ml; NPP Normal pool plasma; OTC Optimal thrombin concentration; PPP Platelet poor plasma; SD Standard deviation; TMAX Limit of measurement of thrombin time; TT Thrombin time; UFH Unfractionated heparin

Indexed keywords

DABIGATRAN; REAGENT; THROMBIN; ANTITHROMBIN;

EID: 84940440202     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.07.018     Document Type: Letter
Times cited : (29)

References (22)
  • 1
    • 84860528205 scopus 로고    scopus 로고
    • Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate
    • J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.M. Dogne Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate Thromb. Haemost. 107 2012 985 997 10.1160/TH11-11-0804
    • (2012) Thromb. Haemost. , vol.107 , pp. 985-997
    • Douxfils, J.1    Mullier, F.2    Robert, S.3    Chatelain, C.4    Chatelain, B.5    Dogne, J.M.6
  • 2
    • 84883238313 scopus 로고    scopus 로고
    • Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate
    • J. Douxfils, J.M. Dogne, F. Mullier, B. Chatelain, Y. Ronquist-Nii, R.E. Malmstrom, and P. Hjemdahl Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate Thromb. Haemost. 110 2013 543 549 10.1160/TH13-03-0202
    • (2013) Thromb. Haemost. , vol.110 , pp. 543-549
    • Douxfils, J.1    Dogne, J.M.2    Mullier, F.3    Chatelain, B.4    Ronquist-Nii, Y.5    Malmstrom, R.E.6    Hjemdahl, P.7
  • 3
    • 84891680866 scopus 로고    scopus 로고
    • Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay
    • R.C. Gosselin, D.M. Dwyre, and W.E. Dager Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay Ann. Pharmacother. 47 2013 1635 1640 10.1177/1060028013509074
    • (2013) Ann. Pharmacother. , vol.47 , pp. 1635-1640
    • Gosselin, R.C.1    Dwyre, D.M.2    Dager, W.E.3
  • 5
    • 84881605571 scopus 로고    scopus 로고
    • Performance of coagulation tests in patients on therapeutic doses of dabigatran: A cross-sectional pharmacodynamic study based on peak and trough plasma levels
    • E.M. Hawes, A.M. Deal, D. Funk-Adcock, R. Gosselin, C. Jeanneret, A.M. Cook, J.M. Taylor, H.C. Whinna, A.M. Winkler, and S. Moll Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels J. Thromb. Haemost. 11 2013 1493 1502 10.1111/jth.12308
    • (2013) J. Thromb. Haemost. , vol.11 , pp. 1493-1502
    • Hawes, E.M.1    Deal, A.M.2    Funk-Adcock, D.3    Gosselin, R.4    Jeanneret, C.5    Cook, A.M.6    Taylor, J.M.7    Whinna, H.C.8    Winkler, A.M.9    Moll, S.10
  • 7
    • 84905019610 scopus 로고    scopus 로고
    • Dabigatran assessment in patients with acute complications using routine coagulation assays
    • L. Stang, S. Nahirniak, K. Butcher, and A.J. Szkotak Dabigatran assessment in patients with acute complications using routine coagulation assays Blood Coagul. Fibrinolysis 25 2014 426 434 10.1097/MBC.0000000000000056
    • (2014) Blood Coagul. Fibrinolysis , vol.25 , pp. 426-434
    • Stang, L.1    Nahirniak, S.2    Butcher, K.3    Szkotak, A.J.4
  • 8
    • 84880798450 scopus 로고    scopus 로고
    • The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples
    • G. Hapgood, J. Butler, E. Malan, S. Chunilal, and H. Tran The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples Thromb. Haemost. 110 2013 308 315 10.1160/TH13-04-0301
    • (2013) Thromb. Haemost. , vol.110 , pp. 308-315
    • Hapgood, G.1    Butler, J.2    Malan, E.3    Chunilal, S.4    Tran, H.5
  • 9
    • 84922394366 scopus 로고    scopus 로고
    • Laboratory measurement of the anticoagulant activity of the non-Vitamin K oral anticoagulants
    • A. Cuker, D.M. Siegal, M.A. Crowther, and D.A. Garcia Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants J. Am. Coll. Cardiol. 64 2014 1128 1139 10.1016/j.jacc.2014.05.065
    • (2014) J. Am. Coll. Cardiol. , vol.64 , pp. 1128-1139
    • Cuker, A.1    Siegal, D.M.2    Crowther, M.A.3    Garcia, D.A.4
  • 10
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
    • J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, M. Feuring, and A. Clemens Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb. Haemost. 103 2010 1116 1127 10.1160/TH09-11-0758
    • (2010) Thromb. Haemost. , vol.103 , pp. 1116-1127
    • Van Ryn, J.1    Stangier, J.2    Haertter, S.3    Liesenfeld, K.H.4    Wienen, W.5    Feuring, M.6    Clemens, A.7
  • 11
    • 0037232986 scopus 로고    scopus 로고
    • Comparison of five thrombin time reagents
    • M.M. Flanders, R. Crist, and G.M. Rodgers Comparison of five thrombin time reagents Clin. Chem. 49 2003 169 172
    • (2003) Clin. Chem. , vol.49 , pp. 169-172
    • Flanders, M.M.1    Crist, R.2    Rodgers, G.M.3
  • 12
    • 84896717555 scopus 로고    scopus 로고
    • Validation of hemostasis and coagulation assays: Recommendations and guidelines
    • R.A. Marlar, J.N. Gausman, and J.W. Engel Validation of hemostasis and coagulation assays: recommendations and guidelines Semin. Thromb. Hemost. 40 2014 186 194 10.1055/s-0033-1364186
    • (2014) Semin. Thromb. Hemost. , vol.40 , pp. 186-194
    • Marlar, R.A.1    Gausman, J.N.2    Engel, J.W.3
  • 13
    • 84886962827 scopus 로고    scopus 로고
    • Initial evaluation of hemostasis: Reagent and method selection
    • S. Kitchen, J. Olson, F. Prestion
    • W. Chandler Initial evaluation of hemostasis: reagent and method selection S. Kitchen, J. Olson, F. Prestion, Quality in Laboratory Hemostasis and Thrombosis 2013 95 104
    • (2013) Quality in Laboratory Hemostasis and Thrombosis , pp. 95-104
    • Chandler, W.1
  • 14
    • 84880571372 scopus 로고    scopus 로고
    • Working Group on Perioperative H. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the working group on perioperative haemostasis (GIHP) - March 2013
    • G. Pernod, P. Albaladejo, A. Godier, C.M. Samama, S. Susen, Y. Gruel, N. Blais, P. Fontana, A. Cohen, J.V. Llau, N. Rosencher, J.F. Schved, E. de Maistre, M.M. Samama, P. Mismetti, and P. Sie Working Group on Perioperative H. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013 Arch. Cardiovasc. Dis. 106 2013 382 393 10.1016/j.acvd.2013.04.009
    • (2013) Arch. Cardiovasc. Dis. , vol.106 , pp. 382-393
    • Pernod, G.1    Albaladejo, P.2    Godier, A.3    Samama, C.M.4    Susen, S.5    Gruel, Y.6    Blais, N.7    Fontana, P.8    Cohen, A.9    Llau, J.V.10    Rosencher, N.11    Schved, J.F.12    De Maistre, E.13    Samama, M.M.14    Mismetti, P.15    Sie, P.16
  • 15
    • 84940444745 scopus 로고    scopus 로고
    • European Medicines Agency C. Pradaxa - EMEA/H/C/000829/X/13/G. (CHMP) CfMPfHU, 2011.
    • European Medicines Agency C. Pradaxa - EMEA/H/C/000829/X/13/G. (CHMP) CfMPfHU, 2011.
  • 16
    • 84893160985 scopus 로고    scopus 로고
    • The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
    • P.A. Reilly, T. Lehr, S. Haertter, S.J. Connolly, S. Yusuf, J.W. Eikelboom, M.D. Ezekowitz, G. Nehmiz, S. Wang, L. Wallentin, and R.-L. Investigators The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J. Am. Coll. Cardiol. 63 2014 321 328 10.1016/j.jacc.2013.07.104
    • (2014) J. Am. Coll. Cardiol. , vol.63 , pp. 321-328
    • Reilly, P.A.1    Lehr, T.2    Haertter, S.3    Connolly, S.J.4    Yusuf, S.5    Eikelboom, J.W.6    Ezekowitz, M.D.7    Nehmiz, G.8    Wang, S.9    Wallentin, L.10    Investigators, R.-L.11
  • 17
    • 0038353977 scopus 로고    scopus 로고
    • Kitchen S, Machin SJ, Lowe GD, Haemostasis, Thrombosis Task Force of the British Committee for Standards in H. Guidelines on fibrinogen assays
    • I.J. Mackie Kitchen S, Machin SJ, Lowe GD, Haemostasis, Thrombosis Task Force of the British Committee for Standards in H. Guidelines on fibrinogen assays Br. J. Haematol. 121 2003 396 404
    • (2003) Br. J. Haematol. , vol.121 , pp. 396-404
    • Mackie, I.J.1
  • 19
    • 84877117204 scopus 로고    scopus 로고
    • Thrombin clotting time
    • V. Ignjatovic Thrombin clotting time Methods Mol. Biol. 992 2013 131 138 10.1007/978[--]1-62703-339-8-10
    • (2013) Methods Mol. Biol. , vol.992 , pp. 131-138
    • Ignjatovic, V.1
  • 20
    • 80052495398 scopus 로고    scopus 로고
    • Toward development of a point-of-care assay of enoxaparin anticoagulant activity in whole blood
    • M.A. Inchiosa Jr., S. Pothula, K. Kubal, V.T. Sanchala, and I. Navarro Toward development of a point-of-care assay of enoxaparin anticoagulant activity in whole blood J. Thromb. Thrombolysis 32 2011 47 53 10.1007/s11239-010-0546-5
    • (2011) J. Thromb. Thrombolysis , vol.32 , pp. 47-53
    • Inchiosa, M.A.1    Pothula, S.2    Kubal, K.3    Sanchala, V.T.4    Navarro, I.5
  • 21
    • 84904368894 scopus 로고    scopus 로고
    • A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time
    • P.K. Chin, D.F. Wright, D.M. Patterson, M.P. Doogue, and E.J. Begg A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time Br. J. Clin. Pharmacol. 78 2014 599 609 10.1111/bcp.12364
    • (2014) Br. J. Clin. Pharmacol. , vol.78 , pp. 599-609
    • Chin, P.K.1    Wright, D.F.2    Patterson, D.M.3    Doogue, M.P.4    Begg, E.J.5
  • 22
    • 84937250263 scopus 로고    scopus 로고
    • Dose tailoring of dabigatran etexilate: Obvious or excessive?
    • J. Douxfils, F. Mullier, and J.M. Dogne Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin. Drug Saf. 1-7 2015 10.1517/14740338.2015.1049995
    • (2015) Expert Opin. Drug Saf. , vol.1-7
    • Douxfils, J.1    Mullier, F.2    Dogne, J.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.